Recent Advances in the Management of Adverse Events Associated with Lorlatinib

Onco Targets Ther. 2023 Sep 5:16:731-738. doi: 10.2147/OTT.S426989. eCollection 2023.


As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.

Keywords: ALK; NSCLC; adverse event; lorlatinib; therapy management.

Publication types

  • Review

Grants and funding

This study was supported by Hunan Pharmaceutical Association Foundation (No: 2020YXH001), Hunan Provincial Natural Science Foundation of China (No: 2021JJ70025), and Climbing Plan of Hunan Cancer Hospital (No: 2021NSFC-A003).